In accordance with the procedures set forth in section 21a-408a-12 of the Regulations of Connecticut State Agencies, the following medical conditions, medical treatments or diseases shall be added to the list of debilitating medical conditions:

1. (a) For patients eighteen years of age or older:

   1. (1) Sickle cell disease;
   2. (2) Post laminectomy syndrome with chronic radiculopathy;
   3. (3) Severe psoriasis and psoriatic arthritis;
   4. (4) Amyotrophic lateral sclerosis;
   5. (5) Ulcerative colitis;
   6. (6) Complex regional pain syndrome, Type 1 and Type II;
   7. (7) Spasticity or Neuropathic Pain Associated with Fibromyalgia;
   8. (8) Severe Rheumatoid Arthritis;
   9. (9) Post Herpetic Neuralgia;
   10. (10) Muscular Dystrophy;
   11. (11) Hydrocephalus with Intractable Headache;
   12. (12) Intractable Headache Syndromes;
   13. (13) Neuropathic Facial Pain;
   14. (14) Osteogenesis Imperfecta;
   15. (15) Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders;
   16. (16) Interstitial Cystitis;
   17. (17) Intractable Neuropathic Pain that is unresponsive to standard medical treatments;
   18. (18) Median Arcuate Ligament Syndrome;
   19. (19) Tourette Syndrome;
   20. (20) Vulvodynia and vulvar burning;
   21. (21) Chronic Pain of at least 6 months’ duration associated with a specified underlying chronic condition refractory to other treatment intervention;
   22. (22) Ehlers-Danlos Syndrome associated with Chronic Pain; and (23) Chronic Pancreatitis.

2. (b) For patients under eighteen years of age:

   1. (1) Muscular Dystrophy;
   2. (2) Osteogenesis Imperfecta;
   3. (3) Intractable Neuropathic Pain that is unresponsive to standard medical treatments;
   4. (4) Tourette Syndrome for patients who have failed standard medical treatment; and(5) Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management.

(Effective March 4, 2016; Amended August 28, 2018; Amended April 30, 2019; Amended October 23, 2019; Amended June 3, 2020; Amended March 24, 2021)